1. Introduction {#sec1}
===============

Stroke represents a major cause of death, followed by cancer and myocardial infarction. Its morbidity and mortality keep increasing during last decades especially in developing countries and bring severe social and economic burdens to patients and their family members. Traditional clinical management includes thrombolytic therapy, percutaneous intravascular interventions, behavioral rehabilitation strategies, and medication such as aspirin. The widely application of thrombolytic therapy is limited by the narrow time window (within 3--4.5 h after acute stroke onset) and serious hemorrhagic complication \[[@B1]--[@B3]\]. Percutaneous intravascular interventions usually need expertise in emergency manipulation, and a series of relative risks exist. Despite active therapies as available above, many patients suffering from stroke often remain disabled and have to rely on natural or forced rehabilitation. The high morbidity and disability of stroke have attracted much attention from clinicians and researchers to explore more effective and safer treatments, especially for those patients unsuitable for thrombolytic therapy and percutaneous intravascular interventions.

There are several events involved in neural cell death in brain of stroke patients \[[@B4]--[@B6]\]. Initially, increased apoptosis, triggered by calcium influx, impaired mitochondria, and energy depletion and followed by glutamate excitotoxicity as a result of oxygen and glucose depletion, plays a pivotal role in cell death. Then, the release of nitric oxide, oxygen free radicals, and other reactive oxygen species cause further damage to neurons. In addition, the abolishment of blood-brain barrier by the release of matrix metalloproteinases (MMPs) and other proteases from endothelial cells allows the infiltration of immune cells. Cytokines released by immune cells lead to inflammatory reaction and increased brain injury. Despite induced neurogenesis by endogeneous NSC found in several stroke models, the number and survival rate of new neurons derived from endogeneous neurogenesis are extremely low and new neurons are insufficient to replace the lost neurons in stroke victims \[[@B7]\].

Ischemia stroke is characterized by acute loss of neurons, astroglia, and oligodendroglia and disruption of synaptic architecture due to cerebral artery occlusion. Endogeneous cell replacement is not enough to repair adult central nervous system (CNS) in patients with stroke because of the limited renewal ability and slow turnover of neural cells. Stem cell therapy has emerged as a novel and promising candidate approach for the treatment of stroke, probably by neuroprotection and neurorepairment via secreting various neural trophic factors and replacing damaged neurons. Most of basic and translational researches are focus on three types of stem cells, including embryonic stem cell (ESCs), neural stem cell (NSCs), and mesenchymal stem cell (MSCs).

2. Embryonic Stem Cells (ESCs) {#sec2}
==============================

ESCs, derived from the inner cell mass of preimplantation embryo, possess the ability of unlimited self-renew and potential of differentiation into virtually any cell types of the organism. The advantage of ESCs is based on its capability of unlimited expansion in vitro to meet the needed amount of cells. In addition, ESCs can be induced to differentiate into neural lineage under specific culturing condition in vitro \[[@B8]--[@B12]\]. Hence, ESCs has been initially considered as an ideal source of transplanted cell for the treatment of neural disorders. After transplantation of mouse ESCs into rat cortex with a severe focal ischemia, ESC-derived cells expressing cell surface markers of neurons, astrocytes, oligodendrocytes, and endothelial cells could be found in the lesion cavity, and improved structural repair and functional recovery has been demonstrated \[[@B13]\]. Intrastriatal transplantation of mouse ESCs or ESC-derived neuron-like cells improved the dopaminergic function and subsequently recovered behavioral dysfunction in focal ischemic rats subjected to middle cerebral artery occlusion (MCAO) \[[@B14]\]. Intracerebral transplantation of mouse ESCs could improve the motor and sensory function of rat with MCAO and reduce the infarct size \[[@B15]\]. The disadvantages of ESC are its malignant transformation and teratoma formation \[[@B16]--[@B18]\]. Ethical concerning, limited sources, and related high incidence of malignant transformation restrict the wide application of ESCs. Hence, the studies about ESCs application in the treatment of stroke were very limited.

Transplantation of differentiated cells derived from ESCs provides a promising way to avoid malignant transformation of ESCs when infused in vivo. The neural derivatives of ESCs represent potential therapeutic cells for stroke. Many studies have explored the effect of ESC-derived neural stem/progenitor cells (NSPC) in animal models of stroke \[[@B23]--[@B22]\]. Most results showed improved behavioral deficit, reduced infarct area, and increased differentiation into neurons after cell transplantation, despite different transplanted cell sources, different stroke animal models, and different infusion routes. However, several studies found that the grafted human ESC-derived neural cells also have the risk of teratomas formation \[[@B24], [@B25]\]. Culturing condition might reduce tumorigenesis risk of transplanted ESC-derived neural cells. For example, neural cells derived from human ESCs under defined inductive culturing condition (named SD56) did not show chromosome abnormalities after differentiation and tumor formation after implantation into ischemic rat brains and naive nude rat brains and flanks \[[@B23]\]. Malignant transformation of ESC-derived neural cells has been demonstrated to be related to postischemic environment probably by the stimulation of various local cytokine \[[@B26]\].

It is widely acknowledged that higher cerebral blood vessel density results in less possibility and later occurrence of patients suffering from stroke. Any therapeutic measure aimed at promoting angiogenesis would play a pivotal role in function recovery of stroke patients. Intra-arterial transplantation of human ESC-derived endothelial cells and mural cells significantly increased cerebral blood vessel and vascular density in the ischemic striatum, followed by reduction of the infarct volume and of apoptosis as well as acceleration of neurological recovery in mice with transient MCAO \[[@B27]\].

3. Inducible Pluripotent Stem Cells (iPSCs) {#sec3}
===========================================

iPSCs, reprogrammed from somatic cells with defined factors, become more attractive in the field of regenerative medicine. iPSCs has been initially induced from mouse embryonic or adult fibroblasts by introducing four factors, Oct3/4, Sox2, c-Myc, and Klf4 \[[@B28]\]. These cells exhibit the morphology and growth properties of ESCs and express ESC marker genes. In vivo subcutaneous transplantation of iPSCs into nude mice results in tumors containing a variety of tissues from all three germ layers. Later, iPSC has also been generated from various cell types including umbilical cord, placental mesenchymal stromal cells, neural stem cells, and adipose-derived precursor cells using the same technique \[[@B29], [@B30]\]. The benefit of iPSCs is the proliferative capacity and multipotential differentiation. In contrast to ESCs, ethical problem can be obviated in iPSC application. Chen et al. investigated the therapeutic effects of subdural transplantation of iPSCs mixed with fibrin glue on cerebral ischemic rats induced by MCAO \[[@B31]\]. It was shown that subdural transplantation of iPSCs can effectively reduce the total infarct volume and greatly improve the behavior of rats with MCAO to perform rotarod and grasping tasks. Attenuation of inflammation response in ischemic brain may be involved in the beneficial and protective effect of iPSCs. In another study, transplantated iPSCs from adult human fibroblasts in rat MCAO model can migrate to the injured brain area, and sensorimotor function has been significantly improved \[[@B32]\]. However, in one study, transplantation of iPSCs into mouse brain of transient MCAO did not lead to behavioral improvement \[[@B33]\]. Notably, it was found that a part of iPSCs differentiated into neuroblasts and neurons, indicating a promising therapeutic approach to supply sufficient neuronal cells for ischemia stroke. One concern with regard to iPSC application is the cellular immunogenicity. It was found that teratomas formed by iPSCs from B6 mouse embryonic fibroblasts were mostly immune-rejected by B6 recipients \[[@B34]\]. In other words, iPSCs, even autologous, might provoke immune rejection. Considering transcription factors of known oncogenicity used in reprogramming process, tumorigenesis property becomes another concern with iPSCs. In fact, iPSCs has been shown to form teratoma after transplanting to the ischemic brain of mice \[[@B33], [@B35]\]. iPSCs have promising potential to treat ischemic stroke if tumorigenesis is properly controlled.

4. Neural Stem Cells (NSCs) {#sec4}
===========================

4.1. Endogenous NSCs {#sec4.1}
--------------------

Adult NSCs are mainly located in the dentate gyrus of the hippocampus, the subventricular zone (SVZ), and the olfactory bulb \[[@B36]\]. Many experimental studies have shown an increased proliferation of NSCs within the SVZ in animal model of MCAO, which persisted at least for four months after ischemia and probably triggered by a series of cytokines and chemokines such as SDF-1, VEGF, monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1 \[[@B37]--[@B41]\]. Several signaling pathways were also involved in stroke-induced neurogenesis including Notch, retinoid, bone morphogenetic protein (BMP), tumor necrosis factor-alpha (TNF-*α*), and sonic hedgehog \[[@B42]--[@B46]\]. Endogenous NSCs function locally by producing neurotrophic factors such as NGF and glial cell line-derived neurotrophic factor (GDNF); regulating the inflammatory environment; producing proangiogenic complexes including netrin-4, laminin, and integrins; and secreting factors promoting synaptic plasticity such as thrombospondins \[[@B48], [@B47]\]. However, the number and survival rate of neuron from these proliferative cells were extremely low, probably because of changed surrounding environment with high concentration of inflammatory cytokines. Various approaches aimed at promoting endogenous neurogenesis by enhancing endogenous NSC proliferation, survival, and differentiation have provided a promising way for the treatment of stroke. For example, increased concentration of some cytokines such as brain derived neurotrophic factor (BDNF) and VEGF in local area by gene modification or direct injection drastically promote the migration of endogeneous NSPC to injured brain areas \[[@B49], [@B50]\]. Erythropoietin (EPO) can enhance the neurogenesis and angiogenesis via BDNF and VEGF in rat stroke model \[[@B51]\]. Sphingosine 1-phosphate (S1P) significantly increased endogenous NPC migration toward the injured central nervous system. S1P2R antagonist upregulates the migration responses induced by S1P, and augments endogenous NPC migration toward the ischemic insult \[[@B52]\]. Recently, minocycline has also been demonstrated to enhance the endogenous NSC activity measured by \[^18^F\]FLT PET in both the SVZ as well as the hippocampus after systemic administration into rats subjected to permanent cerebral ischemia \[[@B53]\]. However, in a large clinical trial, overall death rate of ischemic stroke patients treated with EPO was significantly higher than placebo controls \[[@B54]\]. More and strict preclinical studies are necessary to ensure the safety of biological factors used for promoting endoneurogenesis.

4.2. Exogenous NSCs {#sec4.2}
-------------------

Exogenous NSCs could be obtained from ESCs, iPSCs, bone marrow and adipose-derived MSCs, embryonic NSCs, and fetal and adult nervous systems \[[@B55]\]. These cells could proliferate in vitro when stimulated by various growth factors such as EGF, FGF, and leukemia-inhibiting factor (LIF) and differentiate into neurons, astrocytes, and oligodendrocytes when induced by different factors such retinoic acid. These characteristics of NSCs make them promising candidates for replacement of the lost neural cells in neurodegenerative disorders including stroke. Human fetal NSCs are less tumorigenic than embryonic stem cells, and in a clinical trial using human fetal NSCs in Batten disease, no tumors were detected in five patients 2 years after transplantation \[[@B56]\]. Besides, NSCs express no or low levels of MHC molecules, which obviate the problem of immunorejection \[[@B57]\]. However, there were also experiments showing that the expression of MHC molecules on NSCs was increased under inflammatory conditions \[[@B58], [@B59]\]. Recently, intracerebrally transplanted HUCB-NSC 3 days after ischemia completely disappeared in immunocompetent rat brain tissue at two weeks, probably resulting from innate immune response \[[@B60]\]. The disadvantage of NSCs includes limited capability of expansion and differentiation when cultured in vitro.

In rat model of ischemia stroke, the number of surviving embryonic NSCs was significantly higher than that of adult NSCs, accounting for its more efficient function in reducing lesion volume and improving neuronal function. More prominent Iba-1-positive inflammatory cells of rats receiving adult NSCs might be a rationale for the differences \[[@B61]\]. Indeed, fetal NSCs have stronger capacity of proliferation in vitro and differentiation into neurons in vivo.

Mounting experiments confirmed that transplantation of NSCs derived from various origins via different routes reduced the infarcted area and promoted the neurological function recovery in animal models with ischemic stroke ([Table 1](#tab1){ref-type="table"}), although individual contradictory results also exist. For example, intracerebral injection of NSCs derived from human iPSCs did not reduce the infarct volume and improve functional recovery in rat ischemic stroke model, although NSC could survive and differentiate into neurons \[[@B62]\]. The time, dose, and type of transplanted cell might account for the different results. NSCs in combination with gene modification could enhance their survival, proliferation and migration abilities, and secrete neurotrophic factors if as a gene herapy vehicle. Over expression of some neuroprotective cytokines including VEGF, neurotrophin-3, BDNF, FGF-2, and GDNF has been reported to potentiate the therapeutic effects of transplanted NSCs in stroke animals \[[@B63]--[@B67]\]. Gene modification with HIF-1a also could potentiate the beneficial effect of NSCs on neurological recovery following cerebral ischemia, probably through promoting angiogenesis \[[@B68]\].

### 4.2.1. Transplantation Route {#sec4.2.1}

Stem cells in circulation can migrate into injured brain area probably in response to chemoattractant stimuli through rolling on and adhering to endothelium and endothelial transmigration. VCAM-1 and the integrins *α*2, *α*6, and *β*1 may be involved in the communication between stem cells and endothelium. Then, NSCs are guided into targeted brain area via chemokines such as SDF-1, MCP-1 Ang-1, and Slit \[[@B81]--[@B87]\]. The CCL2/CCR2 interaction has recently been demonstrated to be critical for transendothelial recruitment of intravascularly delivered NSCs in response to ischemic injury \[[@B88]\]. A recent study revealed that the advantageous effect of intracerebral transplantation of NSC in stroke depend on high intracerebral numbers of grafted cells; however, systemic NSC delivery initiates sustained neuroprotection despite low intracerebral numbers of grafted cells via different mechanisms, like stabilization of the BBB and reduction of ROS during early reperfusion \[[@B89]\]. So, compared to intracerebral transplantation, intravascular delivery of NSCs obtains better distribution into the injured brain areas and avoids the process of invasive surgery.

### 4.2.2. Time and Dose of Cell Transplantation {#sec4.2.2}

In a study of rat MCAO model \[[@B90]\], focal transplantation of human NSCs early after stroke (48 hours) resulted in better cell survival than did transplantation 6 weeks after stroke, but the delayed transplantation did not influence the magnitude of migration, neuronal differentiation, and cell proliferation in the grafts. Transplanting greater numbers of NSCs did not result in a greater number of surviving cells or increased neuronal differentiation. Optimal time and dose of cell transplantation change depending on different animal model, cell source, and infusion route. The results of various relative researches are difficult to compare. It was concluded that transplantation before maximal activation of microglia was more beneficial for cell survival.

### 4.2.3. Mechanisms {#sec4.2.3}

The mechanisms underlying the improved functional recovery of ischemic stroke animal model subjected to NSCs therapy remain unclear. Cell replacement was initially recognized as the main mechanism of advantageous effect of transplanted NSCs. In most animal studies, NSCs were found to differentiate into neuronal and/or glial phenotypes \[[@B70], [@B91]--[@B94]\]. Synaptogenesis and functional electrophysiological integration of exogenous NSC into the neuronal circuitry of the host brain has also been demonstrated \[[@B95]\]. However, improved functional recovery could be observed during the time periods while neuronal differentiation has not been achieved. It suggests that cell replacement may not be prerequisite for the effect of stem cell on the neuronal recovery.

*Neuroprotective Effects.*The number of NSCs surviving in the lesion area was too scarce to replace lost neurons. Hence, it was supposed that neuroprotective cytokines secreted by exogenous NSCs, host stem cells, and/or other cells, such as VEGF, BDNF, NGF, and neurotrophins, might play pivotal roles in functional recovery after ischemic stroke directly or indirectly via angiogenesis, immunomodulation, endogenous neurogenesis, and so forth \[[@B96]--[@B98]\]. Increased dendritic plasticity and axonal rewriting in stroke have been linked with paracrine effects of NSCs possibly via VEGF and thrombospondins 1 and 2 \[[@B99]\].

*Endogenous Neurogenesis*. Injection of NSCs into rat cortical infarct cavity has been found to stimulate neurogenesis in the SVZ ipsilateral to stroke, as demonstrated by increased numbers of cells expressing the early neuronal lineage marker Dcx 60 d posttransplant \[[@B100]\]. Transplantation of human embryonic NSCs into cortical peri-infarction in rat 24 h after ischemia increased the number of BrdU^+^ cell in SVZ \[[@B80]\]. Although the experiment did not directly answer whether enhanced neurogenesis contribute to the neurological function improvement, ablation of endogenous neurogenesis in transgenic mice expressing *Herpes simplex virus* thymidine kinase under control of the Dcx promoter increases infarct size and exacerbates postischemic sensorimotor behavioral deficits in another study \[[@B101]\].

*Modulation of Inflammatory and Immune Response*. Inflammatory and immune response mediate secondary injury after acute ischemia insult. Microglia is the main inflammatory regulators in focal brain tissue. It was shown that intravenous administration of NSCs reduced OX-42^+^ microglia and MPO^+^ neutrophil infiltration into brain lesion and also attenuated both cerebral and splenic activations of TNF-a, IL-6, and NF-kB, which promoted neuroprotection in rat stroke model \[[@B102]\]. Some inflammatory regulators, such as TNF-a, IL-1*β*, IL-6, and leptin receptors, have also been downregulated in ischemia brain after transplantation of NPCs \[[@B77]\]. Human immortalized neural stem cell lines (CTX0E03 cell line) has been demonstrated to significantly increase the proliferative DCX^+^ neuroblast in rat MCAO model. The author inferred that concomitantly increased proliferating microglia might mediate this proproliferation effect of CTX0E03 cells \[[@B103]\]. Upregulation of class MHC-I in brain lesion, crucial to neuronal development, differentiation, synaptic plasticity, and behavior, has also been linked with improved neurological function in ischemia rat following NSC transplantation \[[@B76]\].

*Angiogenesis*. Angiogenesis is important for formation of new brain microvessels and functional recovery after ischemic stroke. Enhanced angiogenesis has been associated with functional recovery after NSCs transplantation following stroke \[[@B48], [@B80], [@B104], [@B105]\]. For example, angiogenesis, as indicated by BrdU and vWF staining in cortical peri-infarct regions, has been strengthened by grafted human embryonic NSCs in rat stroke model at 7 and 14 days \[[@B80]\].

5. Mesenchymal Stem Cells (MSCs) {#sec5}
================================

MSCs constitute a population of nonhematopoietic cells in the bone marrow from which these were identified for the first time \[[@B106]\]. Subsequently, MSCs have been successfully isolated from almost all tissues in mammals including circulating blood, UCB, menstrual blood, placenta, heart, adipose tissue, skeletal muscle, pancreas, and dental pulp \[[@B107]\]. Three criteria have been proposed to identify MSCs by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy, including the plastic adherence of the isolated cells in culture, the expression of CD105, CD73, and CD90 in more than 95% of the culture, and their lack of expression of markers including CD34, CD45, and CD14 or CD11b, CD79a or CD19, and HLA-DR in more than 95% of the culture and the differentiation of the MSCs into osteoblasts, adipocytes, and chondroblasts in vitro \[[@B108]\]. MSCs are also capable of differentiating into neural cells, hepatocytes, insulin-producing cells (IPCs), and so forth \[[@B109]\].

The ability of self-renewal and differentiation into neural cells in vitro, as demonstrated by expression of neuronal markers such as NeuN, migration towards sources of lesions in the brain, and non-ethical and tissue-rejection related concerns make MSCs a promising therapeutic approach in stroke treatment. In preclinical experimental studies, transplantation of human or rat MSCs displayed significant effect of functional improvement in animal stroke ([Table 2](#tab2){ref-type="table"}). Gene modification with exogeneous cytokines such as GDNF, BDNF, FGF-2, placental growth factor (PlGF), and angiopoietin-1 fortified the effective roles of MSCs \[[@B110]--[@B114]\].

5.1. Transplantation Route {#sec5.1}
--------------------------

Intravenously or intracerebrally transplanted MSCs could migrate into the injured brain and promote functional improvement in experimental animal models of stroke, although sometimes reduced infarct volume was not observed. The capability of migration of MSCs may be mediated by increased chemokines such as SDF-1 in surrounding environment and CXCR4 presented on MSCs \[[@B115]\]. There are also many other potential factors, such as IL-8, MCP-1, MIP-1a, and VEGF, that might be involved in the migration of MSCs into injured brain \[[@B116], [@B117]\]. Intravenous delivery of MSCs is superior to intracerebral injection because it is less invasive, more extensively neuroprotective, and more easily utilized in clinic.

5.2. Time and Dose of Cell Transplantation {#sec5.2}
------------------------------------------

The optimal dose of cell therapy currently remains unclearly defined. The dose of 1-2 million cells/kg of body weight was suggested for clinical study \[[@B118]\]. The optimal time of transplantation depends on the dynamically changed environment in injured brain. Early delivery of MSCs probably plays neuroprotective roles because of its counteract against increased toxicity and inflammatory response. Transplantation of cells at 2-3 weeks after ischemia probably is more superior in enhancing endogenous neuronal repair such as plasticity, angiogenesis, and neurogenesis, which are more intense at that time. Enhanced functional recovery was observed even at 1 year after administration in ischemic rats \[[@B119]\].

5.3. Mechanisms {#sec5.3}
---------------

Several mechanisms have been explored to account for the beneficial effect of MSCs on experimental stroke model ([Table 2](#tab2){ref-type="table"}). Although MSCs has been demonstrated to be capable of differentiating into cells of neural lineage in vitro and express neuronal or glial markers in ischemic brain of animal models \[[@B110], [@B120], [@B121], [@B122], [@B123]--[@B125]\], the survival number of grafted and differentiated cells only took a small portion. Moreover, some studies explore the function of neuronal cells from MSCs with much controversy \[[@B3], [@B126]--[@B129]\]. Hence, cell replacement might not be mainly responsible for the beneficial effect of MSCs on ischemic brain injury in vivo. MSCs might exert its effects via a series of secreted trophic factors which directly or indirectly promote ischemic brain tissue repair. MSCs is stimulated to secrete various neurotrophic factors including cytokines, chemokines, and extracellular matrix protein by damaged surrounding environment. Secretion of trophic factors by MSCs and/or MSC-stimulated resident cerebral cells has been considered to contribute to the beneficial effects mentioned above. MSCs constitutively express BDNF, which was significantly increased when MSCs was transplanted into MCAO model. MSCs overexpressing BDNF showed stronger therapeutic effects than original MSCs alone \[[@B110]\]. Other neurotrophic factors, such as HGF, VEGF, NGF, bFGF, FGF-2, and IGF-1, have been demonstrated to be implicated in endogenous repair mechanisms mediated by MSCs \[[@B121], [@B132], [@B133], [@B130], [@B131]\]. The trophic factors might play critical roles in neuroprotection, angiogenesis, synaptogenesis, endogenous neurogenesis, and inflammatory and immune response.

### 5.3.1. Neuroprotective Effects {#sec5.3.1}

Several studies found that numerous neurotrophic factors such as SDF-1, VEGF, GDNF, BDNF, NGF, IGF, EGF, and bFGF was significantly increased in ischemic animal brain after MSCs treatment \[[@B120], [@B137]--[@B139], [@B143], [@B145], [@B150], [@B132]\]. These increased neurotrophic factors were secreted by MSCs directly and/or stimulated host cells indirectly. The neuroprotection mediated by these neurotrophic factors including antiapoptosis, increasing neuron survival, antioxidation, antiglutamate excitotoxicity, and anti-inflammatory activity probably account for beneficial effects of MSCs on ischemic brain injury. Recently, MSCs could increase tPA activation and downregulate PAI-1 levels in the ischemic boundary zone, which promote the axonal and synaptophysin production and finally improve functional recovery in rat model of stroke \[[@B135], [@B136]\].

### 5.3.2. Angiogenesis {#sec5.3.2}

Moreover, MSCs have also been described to favour angiogenesis and synaptogenesis \[[@B120], [@B137], [@B140]--[@B143], [@B146], [@B148], [@B154], [@B155]--[@B157]\]. Increased expression of *β*1-integrin, the modulatory effect of macrophage/microglial cells, and enhancement of neurotrophic factor secretion, mediated by MSCs, might contribute to the induction of new vessels \[[@B120]\]. Other trophic factors secreted by MSCs which probably contributed to enhanced angiogenesis include VEGF, BDNF, IGF-1, bFGF, GDNF, and TGF \[[@B151], [@B158], [@B159]\]. In addition, it was found that the number of endothelial progenitor cells markered by CXCR4 was significantly increased in brain of adipose-derived MSC (Ad-MSC) treated ischemic rats. Additionally, Ad-MSC could differentiate into endothelial cell phenotype as demonstrated by vWF staining \[[@B137]\]. These results indicate that differentiation into endothelial cell and/or mobilization of endothelial progenitor cells might be involved in proangiogenic effect of MSCs in stroke. Recently, it was shown that Notch signalling pathway was involved in MSC-induced angiogenesis in ischemic brain \[[@B160]\].

### 5.3.3. Endogenous Neurogenesis {#sec5.3.3}

Notably, increased endogenous neurogenesis might be another mechanism by which MSCs improve the neurological function in ischemic stroke \[[@B137], [@B143], [@B144]\]. When human umbilical cord-derived MSCs were implanted into rats two weeks after MCAO, nestin-positive endogenous stem cells in the hippocampus were significantly increased at 35 days \[[@B144]\]. Intravenous infusion of AdMSCs significantly increased expression of doublecortin in infracted brain area which is an indication of migrating neuroblast \[[@B137]\]. In another study, enhanced proliferation, migration, and differentiation of endogenous neural stem/progenitor cells has also been demonstrated in the SVZ and subgranular zone of the hippocampus when Flk-1^+^ hBMSCs was intracerebrally injected into ischemic brain in rats \[[@B143]\]. It is speculated that enhanced endogenous neurogenesis might be attributed to increased angiogenesis and subsequent improved CBF. Moreover, the influence of the trophic factor cannot be excluded; for example, BDNF can stimulate neurogenesis directly \[[@B161]\].

### 5.3.4. Modulation of Inflammatory and Immune Response {#sec5.3.4}

Inflammatory and immune response modulation by MSCs is a mechanism underlying neuronal protection in ischemic stroke. After Ad-MSCs were intravenously injected into rat model of stroke, mRNA expressions of IL-18, TLR-4, and plasminogen activator inhibitor (PAI)-1 in infarcted brain area, indexes of inflammation, were significantly reduced \[[@B137]\]. hBMSC has been shown to upregulate IL-10 expression in a non-human primate ischemia model, which probably accounts for attenuation of astroglial reactivity, antiapoptotic effect, and neurogenesis \[[@B145]\]. MSCs administration into MCAO rats could cause amplification of activated CD11+ microglia and reactive GFAP+ astrocytes in the peri-infarct area far greater and more long lasting than that seen after stroke alone. Although expression of blood cytokines/chemokines (IL-13, MMP2, and MIP) and growth factors/receptors (VEGF, neuropilin, EPOR, TROY, NGFR, and RAGE) were upregulated following MSCs administration, the causal roles that these blood-borne factors play in improving brain structure and function after MSCs injection in the MCAO rat remain to be validated \[[@B146]\]. However, in one study, systemic inflammatory cytokine levels (IL-6, TNF-*α*, interferon-*γ*, and MCP-1) remained unchanged in the sera of mice after cerebral ischemia and MSCs transplantation \[[@B162]\]. Recently, MSCs has been demonstrated to decrease MCP-1 expression and subsequent infiltration of CD68+ cells in ischemic brain, whereas transplantation of TGF-*β*1-silenced MSCs cannot exert similar effects. Hence, it is reasonable that MSCs secrete TGF-*β*1 to suppress immune propagation in the ischemic rat brain \[[@B163]\].

5.4. Clinical Trials {#sec5.4}
--------------------

12 patients with ischaemic grey matter, white matter, and mixed lesions were included in a nonrandomized, open-label trial. Autologous MSCs, expanded in autologous serum, were delivered intravenously 36--133 days after stroke. There were no cell infusion related side effects such as tumours, abnormal cell growths, neurological deterioration, or venous thromboembolism. As a result, the median daily rate of NIHSS change increased during the first week after infusion, and mean lesion volume as assessed by MRI was reduced by \>20% at 1 week after cell infusion. Although this nonblinded study did not exclude placebo effects or natural recovery of stroke, it provided evidence that transplantation of autologous MSCs is feasible and safe \[[@B164]\].

In a clinical trial, four patients with stroke (three with ischemic and one with hemorrhagic stroke) in the middle cerebral artery territory were recruited. One single dose of 2 × 10^7^ UCMSCs was infused into the MCA. No side effects such as stroke, death, fever, and rash were observed during the 6-month followup. Improved modified Rankin scale was observed in two of the ischemic patients. However, the efficacy and safety of the approach cannot be determined due to small number of enrolled patients and lack of control \[[@B165]\].

In a recent study, 50--60 million bone marrow-derived MSCs were infused intravenously into patients with diagnosed stroke from 3 months to 2 years of index event. There was no mortality or cell related adverse reactions in stem cell-treated patients. Modified Barthel Index (mBI) showed statistical significant improvement in the stem cell group. An increased neural plasticity was observed after stem cell infusion indicating neural plasticity. The authors concluded that stem cells act as "scaffolds" for neural transplantation and may aid in repair mechanisms in stroke \[[@B118]\].

6. Current Concerns {#sec6}
===================

6.1. Cell Homing {#sec6.1}
----------------

Intravenous injection of cells in rats after cerebral ischemia resulted in high accumulation of cells into internal organs such as lungs, liver, and spleen \[[@B166]\]. Intra-arterial infusion was usually accompanied by high incidence of microocclusion, although it could circumvent the filtering organs \[[@B167]\]. Approaches to improve cell homing and efficiency of cell therapy include cell sorting, altered culture conditions, and cell surface modifications. Enrichment of NSCs by FACS for the surface integrin CD49d has been demonstrated to promote cell homing to the area of stroke in mice and improve behavioral recovery \[[@B48]\]. Cell surface engineering may also target cells to tissue of interest. Cells treated with a proteolytic enzyme (pronase) could transiently modify cell surface adhesion proteins \[[@B168]\]. Priming with valproate and/or lithium could promote the homing and migration ability of MSCs in a rat MCAO model, which was likely mediated by VPA-induced CXC chemokine receptor 4 overexpression and lithium-induced matrix metalloproteinase-9 upregulation \[[@B152]\].

6.2. Cell Survival {#sec6.2}
------------------

Several factors may affect cell survival in the acute phase of cerebral infarction, including limited blood supply, hypoxia, trophic factor deficiency, oxidative stress, inflammatory response, and others \[[@B169]\]. Gene modification with various factors such as Bcl-2 and PlGF significantly promoted the survival of ESCs and MSCs \[[@B13], [@B111]\]. Overexpression of growth factor genes including VEGF, GDNF, BDNF, and Akt1 was able to significantly promote the survival of NSCs in stroke animal model \[[@B67], [@B102], [@B170], [@B171]\]. Preconditioning with IL-6 protected the grafted NSCs from ischaemic reperfusion injury in a mouse ischemic stroke model \[[@B172]\]. The survival, proliferative capacity, and paracrine effects of NSCs were enhanced by minocycline preconditioning when intracerebrally transplanted in stroke brain accounting for the improved neurological recovery compared with nonconditioned NSCs. The applications of biomaterial scaffolding also have the potential to enhance the survival of NSCs when intracerebrally transplanted in ischemic brain \[[@B74]\]. Recently, transduction of TAT-heat shock protein 70 (Hsp70) in vitro, which reduces apoptosis and inflammation after hypoxic-ischemic injury, significantly boost the survival of NSCs intracerebrally transplanted in poststroke mice brain \[[@B89]\]. It seemed that hypoxia-treated BMSCs survive better, more BMSCs home to ischemic region, and exhibit a superior property of promoting angiogenesis and neurogenesis after administration into rat subjected to MCAO \[[@B122]\].

6.3. Cell Tracking {#sec6.3}
------------------

In vivo cell tracking also remained an unresolved critical issue. Various cell labeling technique, for example, fluorescent proteins, iron oxide, iron containing agents (e.g., Feridex), magnetodendrimers, particles conjugated with Tat peptides, and paramagnetic particles (gadolinium-diethylene triamine penta-acetic acid \[Gd-DTPA\]) \[[@B173]--[@B175]\], make it possible to track cell fate and migration in combination with MRI after transplantation. There are advantages and shortcomings with regard to labeling efficiency, toxic effects, manufacturing and sensitivity. For example, simple cell endocytosis and lipofectamine-mediated methods of transfection have low labeling efficiencies \[[@B176]\]. It has been demonstrated that supraparamagnetic substances, such as iron oxide, was harmful to cell signaling and function \[[@B177]\]. Magnetodendrimers and particles conjugated with Tat peptides require complicated methods of manufacture. SPECT imaging allows whole body biodistribution studies based on cell labeling with ^111^In-oxine. Besides, this technique also has advantage of high sensitivity, short scanning times, and repeated scanning over several days. The disadvantage mainly include toxicity, and tested signal may come from cell debris rather than surviving cells \[[@B178]\].

6.4. Safety {#sec6.4}
-----------

Safety represents a critical concern before stem cells are allowed to be extensively used in clinic. Recently, a meta-analysis of clinical trials including MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (to June 2011) did not detect associations between MSCs treatment and the development of acute infusional toxicity, organ system complications, infection, death, or malignancy. There was, however, a significant association between MSCs administration and transient fever \[[@B179]\]. Although current clinical trials indicate stem cell therapy for stroke is feasible and safe, robust scientific data is deficient.

6.5. Gene Therapy {#sec6.5}
-----------------

Stem cell-based gene therapy represents a novel potential therapeutic strategy for ischemic stroke in future. Stem cells per se can secret various neurotrophic factors besides as gene delivery vehicles. Transplantation of gene modified-stem cells overexpressing diverse neurotrophic factors such as VEGF, BDNF, GDNF, PIGF, ANG-1, HGF, NGF, EPO, and noggin has been demonstrated to significantly improve the functional recovery in stroke compared to stem cells only \[[@B13], [@B111], [@B140], [@B150], [@B170], [@B180]--[@B183]\]. Overexpression of NGF and noggin in BMSCs could upregulate the presence in ischemic brain and neuronal differentiation of BMSCs.

7. Conclusion {#sec7}
=============

Conclusively, stem cells have become attractive candidates for cell therapy in stroke treatment of which so far no ideal therapeutic measures are available. The beneficial effects of stem cells might include neuroprotection, angiogenesis, inflammatory, and immune response ([Figure 1](#fig1){ref-type="fig"}). Although most animal studies demonstrated that impaired neural function has been significantly improved after administration of various stem cells, many critical issues have to be addressed before clinical application. For example, optimal cell source, dosing, timing and routing, adverse event monitoring, and management need to be urgently determined. Better understanding of the mechanisms of stem cells in treating stroke will help resolve issues above. Large clinical trials are also necessary. In future, stem cell combined with gene therapy will play important roles in experimental and clinical application.
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###### 

Summary of NSC transplantation experiments in ischemic stroke models.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Model           Cell                  Route          Time   Behavioral measures                     Outcome                       Mechanism
  --------------- --------------------- -------------- ------ --------------------------------------- ----------------------------- --------------------------------------------------------------------------
  rMCAO\          fetal hNSC            IC             7 d    NA                                      NA                            Neuronal differentiation
  \[[@B69]\]                                                                                                                        

                                                                                                                                    

  rMCAO\          hNSC                  IV             1 d    TIA, MLPT,\                             IFR                           Migration and differentiation\
  \[[@B70]\]                                                  rotarod test                                                          marker for neurons or astrocytes

                                                                                                                                    

  rMCAO\          hNSC                  IV             24 h   MLPT  \                                 IFR                           ↑EBA immunoreactivities
  \[[@B71]\]                                                  rotarod test                                                          

                                                                                                                                    

  rMCAO\          hESC-derived NSC      IC             7 d    cylinder test                           IFR                           NA
  \[[@B23]\]                                                                                                                        

                                                                                                                                    

  pMCAO\          hNSC                  LT             24 h   mNSS                                    IFR\                          ↑Bcl-2
  \[[@B72]\]                                                                                          no reduced\                   
                                                                                                      infarct size                  

                                                                                                                                    

  rMCAO\          hNSC                  IC             4 w    Bilateral asymmetry test (BAT),  \      IFR.                          Paracrine trophic\
  \[[@B73]\]                                                  rotameter test                                                        endothelial differentiation\
                                                                                                                                    ↑Neurogenesis

                                                                                                                                    

  rMCAO\          hNPC                  LT             3 w    Cylinder test, \                        IFR (sensorimotor/\           ↓Neuronal differentiation
  \[[@B74]\]                                                  adhesive-removal test                   cognitive functions)          

                                                                                                                                    

  PI in cortex\   mNSC                  IV             24 h   Adhesive-removal test                   IFR (sensorimotor function)   ↑Dendritic plasticity\
  \[[@B75]\]                                                                                                                        ↑Activated microglial cells\
                                                                                                                                    ↓Endogenous neurogenesis

                                                                                                                                    

  rMCAO\          Embryonic NSC         IC             1 h    Limb placement test, rotarod test,  \   Reduced infarct volume\       Cell replacement\
  \[[@B61]\]                                                  cylinder test                           IFR                           Trophic effects

                                                                                                                                    

  mMCAO\          CD49d ^+^NSCs         Intracarotid   48 h   Rotarod                                 IFR                           ↑Cell homing
  \[[@B48]\]                                                                                                                        

                                                                                                                                    

  rMCAO\          NSC                   IC\*           7 d    Somatosensory response,  \              IFR                           ↑MHC-I
  \[[@B76]\]                                                  trap channel test                                                     

                                                                                                                                    

  mMCAO\          NPC                   IV             72 h   mNSS                                    IFR                           Anti-inflammatory effect
  \[[@B77]\]                                                                                                                        

                                                                                                                                    

  rICH\           hNSC                  IV             24 h   Rotarod test,  \                        IFR                           Differentiation into neuron and astrocytes
  \[[@B78]\]                                                  modified limb\                                                        
                                                              placing tests                                                         

                                                                                                                                    

  rMCAO\          rNSC and collagen I   IC             24 h   mNSS                                    IFR                           Synapse formation
  \[[@B79]\]                                                                                                                        

                                                                                                                                    

  rMCAO\          embryonic hNSC        IC             24 h   NA                                      NA                            ↑Endogenous cell proliferation in SVZ, angiogenesis in peri-infarct zone
  \[[@B80]\]                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: not assessed; h: human; IC: intracerebral; IV: intravenous; IA: intra-arterial; LT: local transplantation; EBA: endothelial barrier antigen; IFR: improved functional recovery; TIA: turning in an alley test; MLPT: modified limb placing test; PI: photothrombotic ischemia.

###### 

Summary of MSC transplantation experiments in ischemic stroke models.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Model                 Cell                                    Route   Time                                      Behavioral measures                        Outcome                                       Mechanism
  --------------------- --------------------------------------- ------- ----------------------------------------- ------------------------------------------ --------------------------------------------- -------------------------------------------------------------------------------------
  rMCAO\                hUCMSC                                  IC      One week                                  Elevated body swing test,\                 IFR\                                          Neural differentiation into neuron, glia, EC\
  \[[@B120]\]                                                                                                     locomotor activity                         ↑neuronal activity                            ↑Neurotrophic factors (SDF-1, GDNF, BDNF)\
                                                                                                                                                                                                           ↑Angiogenesis

                                                                                                                                                                                                           

  rMCAO\                BMSC                                    ICA     24 h                                      Rotarod test\                              IFR                                           Production of trophic factors
  \[[@B134]\]                                                                                                     adhesive-removal test\                                                                   
                                                                                                                  mNSS                                                                                     

                                                                                                                                                                                                           

  mMCAO\                BDNF-modified hBMSC                     IC      24 h                                      Limb placement test,\                      IFR                                           ↓Apoptosis;\
  \[[@B110]\]                                                                                                     treadmill test                                                                           Differentiation (NeuN, GFAP)

                                                                                                                                                                                                           

  mMCAO\                mBMSC                                   IV      1 d                                       NA                                         NA                                            ↑tPA\
  \[[@B135]\]                                                                                                                                                                                              ↓PAI-1

                                                                                                                                                                                                           

  mMCAO\                mBMSC                                   IV      1 d                                       mNSS\                                      IFR; ↓lesion volume                           ↑tPA level
  \[[@B136]\]                                                                                                     Foot-fault tests                                                                         

                                                                                                                                                                                                           

  rMCAO\                Ad MSC                                  IV      0, 12 and 24 h                            Corner test                                ↓infarct area\                                ↑Angiogenesis, neurogenesis, homing\
  \[[@B137]\]                                                                                                                                                IFR (sensorimotor)                            ↓Apoptosis, inflammation, and oxidation

                                                                                                                                                                                                           

  rMCAO\                hBMSC                                   IV      1 d                                       mNSS                                       IFR                                           ↑Growth factors; ↓apoptosis\
  \[[@B138]\]                                                                                                                                                                                              proliferated endogenous cells

                                                                                                                                                                                                           

  rMCAO\                hBMSC                                   IV      12 h                                      Morris water maze,\                        IFR\                                          Neuroprotective effect
  \[[@B139]\]                                                                                                     treadmill test                             ↓lesion volume                                

                                                                                                                                                                                                           

  rMCAO\                Ang-1 modified hBMSC                    IV      6 h                                       Treadmill stress test                      IFR\                                          ↑Angiogenesis
  \[[@B140]\]                                                                                                                                                ↓gross lesion volume                          

                                                                                                                                                                                                           

  rMCAO\                pMSC                                    IV      6 h                                       Treadmill stress test                      IFR\                                          ↑Induced angiogenesis
  \[[@B141]\]                                                                                                                                                ↓lesion volume                                

                                                                                                                                                                                                           

  rMCAO\                hBMSC                                   IV      6 h or 6, 24, 48 h                        Treadmill stress test                      IFR\                                          ↑Capillary vessels
  \[[@B142]\]                                                                                                                                                ↓lesion volume                                

                                                                                                                                                                                                           

  rMCAO\                Human BMSC                              IC      3 d                                       mNSS adhesive-removal somatosensory test   IFR, ↓infarct volume and↑glucose metabolism   ↑Angiogenesis\
  \[[@B143]\]                                                                                                                                                                                              ↑Endogenous neurogenesis ↓Apoptosis

                                                                                                                                                                                                           

  rMCAO\                MSC                                     IA      1 d                                       Adhesive-removal, mNSS                     IFR                                           Differentiation into astrocytes and neurons
  \[[@B121]\]                                                                                                                                                                                              

                                                                                                                                                                                                           

  rMCAO\                hUC-MSC                                 IC      14 d                                      Neurobehavioral assessment\                IFR\                                          Neuroprotective effects\
  \[[@B144]\]                                                                                                     neurologic deficit score                   ↓infarct volume                               ↑Endoneurogenesis

                                                                                                                                                                                                           

  ape ischemia model\   hBMSC                                   IC      7 d                                       mNSS                                       IFR\                                          ↑IL-10, neurogenesis\
  \[[@B145]\]                                                                                                                                                ↓ischemia area                                ↓Astroglial reactivity and apoptosis

                                                                                                                                                                                                           

  rMCAO\                rBMSC or hBMSC                          IV      1 d or 7 d                                mNSS                                       IFR                                           ↑Activated CD11+ microglia, reactive GFAP+ astrocytes, and blood vessel formation\
  \[[@B146]\]                                                                                                                                                                                              modified blood levels of specific cytokines/chemokines and growth factors/receptors

                                                                                                                                                                                                           

  rMCAO\                rBMSC                                   ICA     2 h                                       NA                                         ↓lesion size                                  Activated microglia
  \[[@B147]\]                                                                                                                                                                                              

                                                                                                                                                                                                           

  rMCAO\                rBMSC                                   IV      on the day of MCAO and three days later   Morris water maze                          IFR\                                          ↑Angiogenesis and subventricular zone cells proliferation
  \[[@B148]\]                                                                                                                                                Reduction of the infarct volumes              

                                                                                                                                                                                                           

  mTCCO\                hBMSC                                   ICA     1 d                                       Open-field behavior test                   IFR                                           ↓Neuronal death and\
  \[[@B149]\]                                                                                                                                                                                              modulation of inflammatory and immune responses

                                                                                                                                                                                                           

  rMCAO\                Gene-transferred MSCs                   IC      2 h or 24 h                               mNSS                                       IFR\                                          Neuroprotective effect
  \[[@B150]\]                                                                                                                                                ↓infarction areas                             

                                                                                                                                                                                                           

  rMCAO\                hBMSC                                   IV      1 d                                       mNSS                                       IFR                                           ↑IGF-1, IGF-1R
  \[[@B132]\]                                                                                                                                                                                              

                                                                                                                                                                                                           

  rMCAO\                BMSC                                    IV      24 h                                      mNSS\                                      IFR\                                          ↑trophic factor
  \[[@B151]\]                                                                                                     foot-fault tests                           no difference in ischemic volume              

                                                                                                                                                                                                           

  rMCAO\                hypoxic preconditioned or normal BMSC   IV      24 h                                      Rotarod test                               IFR                                           ↓Microglia activity\
  \[[@B122]\]                                                                                                                                                                                              ↑Differentiation into neuronal and vascular endothelial cells

                                                                                                                                                                                                           

  rMCAO\                B10 line of hMSC                        IV      24 h                                      mNSS score                                 IFR\                                          Providing IGF-1\
  \[[@B133]\]                                                                                                                                                ↓infarct volume                               inducing VEGF, EGF, and bFGF in host brain

                                                                                                                                                                                                           

  rMCAO\                Valproate/\                             IV      24 h                                      Rotarod test, mNSS\                        IFR\                                          ↑CXCR 4, MMP-9
  \[[@B152]\]           lithium-primed MSC                                                                        body asymmetry test                        ↓infarct volume\                              
                                                                                                                                                             ↑angiogenesis                                 

                                                                                                                                                                                                           

  rMCAO\                pMSC                                    IV      8 h\                                      Beam walk test\                            IFR\                                          Immunomodulation\
  \[[@B153]\]                                                           8 h and 24 h                              mNSS                                       ↓lesion volume                                soluble factor secretion\
                                                                                                                                                                                                           ↑Astroglial reactivity

                                                                                                                                                                                                           

  rMCAO\                BM-MSC Ad-MSC                           IV      30 min                                    Rogers and rotarod tests                   IFR\                                          ↑VEGF, SYP, Olig2, NF; decreased GFAP
  \[[@B154]\]                                                                                                                                                no reduction in infarct volume                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

h: human; p: human placenta; Ad: adipose-derived; m: mouse; r: rat; ICA: intracarotid arterial; IC: intracerebral; IV: intravenous; IA: intra-arterial; mNSS: modified neurological severity score; IFR: improved functional recovery; NA: not assessed.
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